Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
Roshan PK, Assistant Professor, Emergency Physician at Government Medical College, posted on LinkedIn:
”Breaking Down Pulmonary Embolism (PE) Treatment by Risk Level
From the 2022 NEJM Review on Pulmonary Embolism – a comprehensive guide by Kahn and de Wit:
Low-Risk PE (Stable, no RV strain or elevated biomarkers):
• Start with oral anticoagulants like apixaban (10mg 2x/day for 7 days, then 5mg 2x/day) or rivaroxaban.
• Outpatient treatment often safe if no other concerns.
• No thrombolysis or embolectomy needed.
• Duration: At least 3 months; longer if high recurrence risk.
Intermediate-Risk PE (Stable but with RV dysfunction or high biomarkers):
• Immediate low-molecular-weight heparin (LMWH) for anticoagulation.
• Hospital monitoring essential – watch for worsening.
• Thrombolysis only if deteriorating (systemic preferred; catheter-directed as alternative).
• Embolectomy if high bleeding risk or near-shock.
• Same duration as low-risk.
High-Risk PE (Unstable with hypotension/shock):
• IV unfractionated heparin + reperfusion therapy.
• Systemic thrombolysis first if no high bleeding risk.
• Surgical or catheter-directed embolectomy if thrombolysis contraindicated or fails.
• Urgent action to stabilize
Remember, risk stratification uses hemodynamics, imaging, and biomarkers. Always seek professional medical advice – this is for info only.”
Stay updated with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation